Cargando…

The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution

Coronavirus disease 2019 (COVID-19) is a worldwide public health and economic threat, and virus variation amplifies the difficulty in epidemic prevention and control. The structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been studied extensively and is now well defined. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Ye, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537874/
https://www.ncbi.nlm.nih.gov/pubmed/37766148
http://dx.doi.org/10.3390/vaccines11091472
_version_ 1785113196661571584
author Liu, Ying
Ye, Qing
author_facet Liu, Ying
Ye, Qing
author_sort Liu, Ying
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a worldwide public health and economic threat, and virus variation amplifies the difficulty in epidemic prevention and control. The structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been studied extensively and is now well defined. The S protein is the most distinguishing feature in terms of infection and immunity, mediating virus entrance and inducing neutralizing antibodies. The S protein and its essential components are also the most promising target to develop vaccines and antibody-based drugs. Therefore, the key site mutation in the S gene is of high interest. Among them, RBD, NTD, and furin cleavage sites are the most mutable regions with the most mutation sites and the most serious consequences for SARS-CoV-2 biological characteristics, including infectivity, pathogenicity, natural immunity, vaccine efficacy, and antibody therapeutics. We are also aware that this outbreak may not be the last. Therefore, in this narrative review, we summarized viral variation and prevalence condition, discussed specific amino acid replacement and associated immune challenges and attempted to sum up some prevention and control strategies by reviewing the literature on previously published research about SARS-CoV-2 variation to assist in clarifying the mutation pathway and consequences of SARS-CoV-2 for developing countermeasures against such viruses as soon as possible.
format Online
Article
Text
id pubmed-10537874
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105378742023-09-29 The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution Liu, Ying Ye, Qing Vaccines (Basel) Review Coronavirus disease 2019 (COVID-19) is a worldwide public health and economic threat, and virus variation amplifies the difficulty in epidemic prevention and control. The structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been studied extensively and is now well defined. The S protein is the most distinguishing feature in terms of infection and immunity, mediating virus entrance and inducing neutralizing antibodies. The S protein and its essential components are also the most promising target to develop vaccines and antibody-based drugs. Therefore, the key site mutation in the S gene is of high interest. Among them, RBD, NTD, and furin cleavage sites are the most mutable regions with the most mutation sites and the most serious consequences for SARS-CoV-2 biological characteristics, including infectivity, pathogenicity, natural immunity, vaccine efficacy, and antibody therapeutics. We are also aware that this outbreak may not be the last. Therefore, in this narrative review, we summarized viral variation and prevalence condition, discussed specific amino acid replacement and associated immune challenges and attempted to sum up some prevention and control strategies by reviewing the literature on previously published research about SARS-CoV-2 variation to assist in clarifying the mutation pathway and consequences of SARS-CoV-2 for developing countermeasures against such viruses as soon as possible. MDPI 2023-09-10 /pmc/articles/PMC10537874/ /pubmed/37766148 http://dx.doi.org/10.3390/vaccines11091472 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liu, Ying
Ye, Qing
The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
title The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
title_full The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
title_fullStr The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
title_full_unstemmed The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
title_short The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
title_sort key site variation and immune challenges in sars-cov-2 evolution
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537874/
https://www.ncbi.nlm.nih.gov/pubmed/37766148
http://dx.doi.org/10.3390/vaccines11091472
work_keys_str_mv AT liuying thekeysitevariationandimmunechallengesinsarscov2evolution
AT yeqing thekeysitevariationandimmunechallengesinsarscov2evolution
AT liuying keysitevariationandimmunechallengesinsarscov2evolution
AT yeqing keysitevariationandimmunechallengesinsarscov2evolution